Zobrazeno 1 - 10
of 36
pro vyhledávání: '"genetically engineered biological preparations"'
Autor:
Andrey L. Bakulev, Olga A. Pritulo, Zhanna S. Kuntsevich, Alkes A. Khotko, Anastasiya A. Yunovidova, Pavel V. Gorognichev, Oleg R. Ziganshin, Natalya S. Rudneva, Evgeniya V. Bildyuk, Tatiana V. Repina, Valentina Y. Dudko, Mariya D. Maksimova
Publikováno v:
Vestnik Dermatologii i Venerologii, Vol 99, Iss 5, Pp 84-95 (2023)
Rationale. Data from randomized clinical trials (RCTs) may differ from the results of the efficacy and safety of medicines in the conditions of daily work. Purpose. To obtain data on the long-term efficacy and safety of the use of the genetically
Externí odkaz:
https://doaj.org/article/f6a5cd60fbb64a938817a2062f15e986
Publikováno v:
Антибиотики и Химиотерапия, Vol 67, Iss 3-4, Pp 70-76 (2022)
Background. The issues of vaccination against the herpesvirus infection are still important in rheumatological practice.This infection often develops in patients receiving immunosuppressive treatment, especially Janus kinase inhibitors (a class-speci
Externí odkaz:
https://doaj.org/article/dccc84f9b2704e108573cfba688ca634
Publikováno v:
Безопасность и риск фармакотерапии, Vol 10, Iss 1, Pp 34-47 (2022)
Monoclonal antibodies directed against interleukin and interleukin receptors have been successfully used for the treatment of rheumatic diseases since 2001, and since 2020 they have been used as part of complex therapy for patients with severe COVID-
Externí odkaz:
https://doaj.org/article/baac869b385b49d8a236d5d248a32c87
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 2, Pp 222-228 (2019)
In the article the analysis of the literature on the impact of biologics of different groups (inhibitors of tumor necrosis factor α, tocilizumab, abatacept, rituximab and interleukin 1 inhibitors) on the production of insulin by the pancreas, insuli
Externí odkaz:
https://doaj.org/article/7f38031f4b704efa843385e8d61e8187
Safety and efficiency of therapy by gene-engineering-biological preparations of rheumatoid arthritis
Autor:
E. A. Strel’tsov
Publikováno v:
Медицинский вестник Юга России, Vol 9, Iss 3, Pp 44-49 (2018)
In this review of the literature, questions of the efficacy and safety of therapy with genetically engineered biological preparations for rheumatoid arthritis are discussed. The results of randomized trials of recent years are described in detail. Sy
Externí odkaz:
https://doaj.org/article/89f60ed850ca4deba4011045cea7a8d3
Autor:
Ekaterina V. Denisova, Ekaterina I. Alexeeva, Tatyana M. Dvoryakovskaya, Margarita A. Soloshenko, Anna V. Mamutova, Kseniya B. Isayeva, Anna N. Fetisova
Publikováno v:
Вопросы современной педиатрии, Vol 17, Iss 4, Pp 328-332 (2018)
Background. Insufficient efficacy or intolerance of the first TNF-α inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the appointment of a second inhibitor. Golimumab is a new TNF-α inhibitor registered for treatin
Externí odkaz:
https://doaj.org/article/153b4b2d4fa04a8d8149fad6603cb7ce
Autor:
M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov
Publikováno v:
Фармакоэкономика, Vol 11, Iss 2, Pp 44-52 (2018)
The existing model of financial support of medical assistance for clinical-statistical groups (CSGs) in 2018 provides for the reimbursement for hospital stay expenses by the compulsory medical insurance fund in patients claiming the need for genetica
Externí odkaz:
https://doaj.org/article/7878ec88e6eb446b88294a01e4459650
Publikováno v:
Терапевтический архив, Vol 90, Iss 2, Pp 4-11 (2018)
Personalized medicine (personalized medicine, individualized medicine) represents the totality of methods of prevention of a pathological condition, diagnosis and treatment in the event of its occurrence, based on individual patient characteristics.
Externí odkaz:
https://doaj.org/article/29d6ded088c245279fd08be12e9b9278
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 5, Iss 6, Pp 568-580 (2018)
Clinical practice and content analysis of scientifi c literature indicate that for treatment of the immune-infl amatory disease called juvenile rheumatoid arthritis (JRA), the use of only basic medicines (BM) is not suffi cient.The aim of the study i
Externí odkaz:
https://doaj.org/article/31e7991d4d62420a9d73b5937d05a7be
Autor:
Ekaterina I. Alexeeva, Tatiana M. Dvoryakovskaya, Rina V. Denisova, Olga L. Lomakina, Anna V. Karaseva
Publikováno v:
Вопросы современной педиатрии, Vol 16, Iss 4, Pp 314-320 (2017)
The article presents a case of a severe progressive course of polyarticular juvenile idiopathic arthritis, debuting at an early age, refractory to the therapy with methotrexate, cyclosporine, and glucocorticosteroids. A clinical example demonstrates
Externí odkaz:
https://doaj.org/article/2b6eb48eb93442c999dbab56dd8a1515